Evidence map›Paper›PMID 42459333›Full record

ArticleFrontiers in cellular and infection microbiology2026

Juan P Cárdenas, Boris Vidal-Veuthey, Kevin Meza, Daniel E Almonacid, Anastasia Gutkevich

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan P CárdenasDepartamento de Ciencias Biológicas, Facultad Ciencias de la Vida, Universidad Andres Bello, Santiago, Chile.
Boris Vidal-VeutheyCentro de Genómica y Bioinformática, Facultad de Ciencias, Ingeniería y Tecnología, Universidad Mayor, Santiago, Chile.
Kevin MezaR & D Department, Bifidice SpA, Santiago, Chile.
Daniel E AlmonacidR & D Department, Bifidice SpA, Santiago, Chile.
Anastasia GutkevichR & D Department, Bifidice SpA, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bifidobacterium bifidum is a key member of the human gut microbiota with well-recognised roles in intestinal homeostasis, glycan metabolism, and immunomodulation. Strain 900791, isolated from the meconium of a Siberian infant, has been used as a commercial probiotic ingredient for decades and has demonstrated, in previously published clinical trials, an ability to improve lactose tolerance and reduce gastrointestinal symptoms in both children and adults; however, the genomic basis for these properties has not been characterised. Methods: We present the complete genome sequence and comprehensive in silico genomic and pangenomic analysis of B. bifidum strain 900791. Hybrid sequencing was used for genome assembly. Phylogenomic analysis, including core genome MLST (cgMLST), integrated 229 high-quality B. bifidum genomes, representing the largest dataset for this species to date. Functional annotation and carbohydrate-active enzyme (CAZyme) profiling, antimicrobial resistance prediction, and bioinformatic screening for probiotic-associated genomic features were also performed. Results: Hybrid sequencing yielded a single circular chromosome of 2,280,092 bp, comprising 1,852 protein-coding sequences. Phylogenomic analysis revealed that strain 900791 belongs to a clonal subgroup of nine closely related strains (>99% cgMLST identity), consistent with a geographically structured lineage. The species pangenome comprised 4,152 orthogroups and a core of 1,450 gene families; 23 orthogroups were exclusive to the 900791 clonal subgroup, including a predicted lantibiotic biosynthetic cluster. CAZyme profiling identified glycoside hydrolase families associated with human milk oligosaccharide degradation (GH2, GH20, GH33, GH84), mucin glycan cleavage (including ten GH families), and lactose metabolism (GH2, GH42). Safety assessment identified only species-typical resistance to mupirocin and rifampicin, with no acquired resistance markers. Bioinformatic screening of the clonal subgroup detected the presence of adhesion-associated proteins, acid resistance systems, bile salt tolerance determinants, oxidative stress response proteins, and two putative bacteriocin gene clusters. Discussion: These findings provide a genomic framework consistent with the documented clinical role of strain 900791 in lactose tolerance and support its further investigation as a candidate probiotic. The probiotic-associated features identified here may help explain its observed properties and represent priority targets for experimental validation in future in vitro and in vivo studies.

Indexed as

Bifidobacterium bifidumGenome, BacterialComputational BiologyComputer SimulationDrug Resistance, BacterialGenomicsHumansMultilocus Sequence TypingPhylogenyProbioticsSequence Analysis, DNAWhole Genome SequencingBifidobacterium bifidumpangenomeprobioticsprobiotic traitswhole genome sequencing

Identifiers

PMID42459333
PMCPMC13368793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.